Skip to content

Evidence for PrEP efficacy grows, but implementation presents challenges

Carl Dieffenbach at the 2015 National HIV Prevention Conference. Photo by Liz Highleyman, hivandhepatitis.com

Tenofovir alafenamide fumarate at what price? No more than $1000 a year above existing tenofovir formulation, says model

Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings

US syringe funding ban impedes HIV and hepatitis C prevention

Bill McColl and Mary Beth Levin at the National HIV Prevention Conference. Photo by Liz Highleyman, hivandhepatitis.com

UK maintains the largest HIV epidemic in western Europe

Sofosbuvir/daclatasvir combination could be produced for $200 per hepatitis C cure

Drug resistance acquired during HIV PrEP rapidly disappears after medication is discontinued

Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection

Jurgen Rockstroh, presenting at AASLD 2015. Photo by Liz Highleyman, hivandhepatitis.com

Death during MDR-TB treatment more likely in people with HIV and underweight or most drug-resistant patients